Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. (3rd August 2018)

• Record Type: Journal Article
• Authors: Takagi, Toshio; Yoshida, Kazuhiko; Kobayashi, Hirohito; Kondo, Tsunenori; Iizuka, Junpei; Okumi, Masayoshi; Ishida, Hideki; Fukuda, Hironori; Ishihara, Hiroki; Tanabe, Kazunari
• Is Part Of: Japanese journal of clinical oncology. Volume 48:Number 9(2018)
• Page Start: 860
• Page End: 863
• Publication Date: 2018-08-03
• Subjects: kidney neoplasm -- metastatic -- response; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyy106
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract : A relatively durable response was observed in three patients after discontinuing nivolumab treatment. Abstract: We investigated the efficacy of nivolumab treatment in patients with metastatic renal cell carcinoma who discontinued nivolumab treatment due to reasons other than disease progression. Of the 34 patients, 3 patients discontinued nivolumab therapy due to adverse events and were subsequently observed without additional treatment. The first patient discontinued nivolumab after 14 cycles of treatment due to type 1 diabetes mellitus and has maintained partial remission for 8 months. The second patient discontinued nivolumab after 11 cycles of treatment due to interstitial pneumonitis, and durable response was confirmed for 5 months. However, multiple lung lesions reappeared at 6 months after discontinuing nivolumab. The third patient discontinued nivolumab due to elevated liver enzymes after three cycles of treatment. At the time of discontinuation, a new liver lesion appeared, but the lesion decreased in size at 6 months after discontinuation. In the present study, a relatively durable response was observed in three patients who discontinued nivolumab without additional treatment.